Document is current

Any future updates will be listed below

Migräne-Prophylaxe mit Erenumab: Abbruchrate langfristig niedrig

Crossref DOI link: https://doi.org/10.1007/s15202-021-4716-4

Published Online: 2021-08-06

Published Print: 2021-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark